Pharmaceuticals

Anemia And Other Blood Disorder Drugs Market Research: Growth Projections and Trends 2030

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the anemia and other blood disorder drugs market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Anemia And Other Blood Disorder Drugs Market in 2030?

The anemia and other blood disorder drugs market size has demonstrated significant expansion in recent years. It is anticipated to grow from $12.46 billion in 2025 to $13.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. The historical rise in this market can be ascribed to a high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, the reliance on blood transfusions, the long-standing use of ESAs, and established hematology treatment protocols.

The anemia and other blood disorder drugs market size is projected to experience significant expansion over the next few years. It is forecast to reach $16.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This growth during the forecast period is attributable to factors such as the increasing adoption of gene therapy, a rising aging population, greater awareness of blood disorders, the proliferation of specialty hematology clinics, and improved diagnostic rates. Prominent trends expected in this period include the increasing prevalence of chronic blood disorders, a growing reliance on injectable therapies, the wider application of gene therapy for rare anemias, an intensified focus on personalized hematology treatments, and enhanced access to essential blood disorder drugs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

What Drivers Are Influencing Production Trends In The Anemia And Other Blood Disorder Drugs Market?

The increasing need for personalized medicine is anticipated to boost the expansion of the anemia and other blood disorder drugs market in the future. This medical strategy tailors prevention, diagnosis, and treatment decisions based on an individual’s unique genetic makeup. The growing interest in personalized medicine stems from its capacity to offer more precise and effective treatments, leading to better patient results and enhanced long-term well-being. The anemia and other blood disorder drugs market facilitates personalized care through customized treatment regimens designed to target the distinct genetic or molecular traits of various blood disorders. As an illustration, data from May 2024 by the American Psychiatric Association, a US-based non-profit organization, indicates that 43% of adults reported increased anxiety compared to the previous year, an uptick from 37% in 2023 and 32% in 2022. Consequently, the increasing need for personalized medicine is a key factor propelling the expansion of the anemia and other blood disorder drugs market.

Which Segment Groups Are Influencing The Anemia And Other Blood Disorder Drugs Market?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

Which Market Trends Are Opening Growth Opportunities In The Anemia And Other Blood Disorder Drugs Market?

Leading companies involved in the anemia and other blood disorder drugs market are prioritizing the introduction of novel medications, with the goal of enhancing therapeutic outcomes, expanding treatment possibilities, and strengthening their market position. These novel medications represent innovative pharmaceutical therapies that present new mechanisms of action, superior efficacy, or improved safety profiles when compared to existing treatments, addressing unmet medical needs in conditions such as anemia and myelodysplastic syndromes. For example, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, obtained FDA approval for Reblozyl for use as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. This marks the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this setting, a finding supported by Phase 3 COMMANDS trial data which showed that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence coupled with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.

Who Are The Core Companies Influencing Trends In The Anemia And Other Blood Disorder Drugs Market?

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Which Regions Are Projected To Dominate The Anemia And Other Blood Disorder Drugs Market In The Coming Years?

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Anemia And Other Blood Disorder Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2465&type=smp

Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795